2025
Outcomes in management of locally advanced rectal cancer with total neoadjuvant therapy in an underserved population.
Ganguly A, Paladiya R, Ingawale S, Giri S, Abbagoni V, Thumar J. Outcomes in management of locally advanced rectal cancer with total neoadjuvant therapy in an underserved population. Journal Of Clinical Oncology 2025, 43: 208-208. DOI: 10.1200/jco.2025.43.4_suppl.208.Peer-Reviewed Original ResearchTNT groupTotal neoadjuvant therapyLocally advanced rectal cancerAdvanced rectal cancerManagement of locally advanced rectal cancerTumor locationNeoadjuvant therapyConventional therapyRectal cancerCT groupPropensity score matchingLow tumorsHigh tumorNo responsePathologic response to treatmentTreating locally advanced rectal cancerResponse ratePartial response ratePathological response rateScore matchingFisher's exact testResponse to treatmentComplete responseAdjuvant treatmentUnderserved populationsSacral tumors: a comprehensive review of imaging, diagnostic challenges, and tumor mimics
Adin M, Woolf G, Hegde R, Elsamadicy A, Mendel E, Zucconi W, Pucar D, Aygün N. Sacral tumors: a comprehensive review of imaging, diagnostic challenges, and tumor mimics. Skeletal Radiology 2025, 1-26. PMID: 39821683, DOI: 10.1007/s00256-024-04862-6.Peer-Reviewed Original ResearchPrimary tumorTumor mimicsImaging findingsAssessment of response to treatmentGerm cell tumorsEvaluation of systemic diseasesResponse to treatmentInsufficiency fracturesSacral massSecondary tumorsCell tumorsPretreatment evaluationDiagnostic challengeLymphoproliferative diseaseClinical detailsMalignant tumorsPrimary modalitySystemic diseaseEwing sarcomaTumorNotochordal remnantsDevelopmental entityEpidemiological factorsDiagnosisMetastasisProspective validation of ORACLE, a clonal expression biomarker associated with survival of patients with lung adenocarcinoma
Biswas D, Liu Y, Herrero J, Wu Y, Moore D, Karasaki T, Grigoriadis K, Lu W, Veeriah S, Naceur-Lombardelli C, Magno N, Ward S, Frankell A, Hill M, Colliver E, de Carné Trécesson S, East P, Malhi A, Snell D, O’Neill O, Leonce D, Mattsson J, Lindberg A, Micke P, Moldvay J, Megyesfalvi Z, Dome B, Fillinger J, Nicod J, Downward J, Szallasi Z, Hackshaw A, Jamal-Hanjani M, Kanu N, Birkbak N, Swanton C. Prospective validation of ORACLE, a clonal expression biomarker associated with survival of patients with lung adenocarcinoma. Nature Cancer 2025, 6: 86-101. PMID: 39789179, PMCID: PMC11779643, DOI: 10.1038/s43018-024-00883-1.Peer-Reviewed Original ResearchConceptsLung adenocarcinomaStage I diseaseClinicopathological risk factorsSurvival of patientsResponse to treatmentRNA sequencing dataI diseaseSequence dataMetastatic clonesNeedle biopsyIndividual tumorsLung expressionTranscription signalsPrognostic informationWhole exomeExpressed genesChemotherapy sensitivityProspective validationSurvival associationsTranscriptomic heterogeneityHuman tumorsEvolutionary measuresChromosomal instabilityRisk factorsNatural history
2024
Insulin clearance at randomisation and in response to treatment in youth with type 2 diabetes: a secondary analysis of the TODAY randomised clinical trial
Nadeau K, Arslanian S, Bacha F, Caprio S, Chao L, Farrell R, Hughan K, Rayas M, Tung M, Cross K, El ghormli L. Insulin clearance at randomisation and in response to treatment in youth with type 2 diabetes: a secondary analysis of the TODAY randomised clinical trial. Diabetologia 2024, 68: 676-687. PMID: 39706874, DOI: 10.1007/s00125-024-06327-w.Peer-Reviewed Original ResearchConceptsYouth-onset type 2 diabetesType 2 diabetesBeta cell functionRandomised clinical trialsVisceral adipose tissueMarkers of adiposityInsulin sensitivityInsulin clearanceSubcutaneous adipose tissueCell functionClinical trialsResponse to rosiglitazone treatmentDual-energy X-ray absorptiometryPersistently elevated blood glucose levelsMarkers of insulin sensitivityFasting blood testsX-ray absorptiometryFasting C-peptideNon-Hispanic black raceAdipose tissueResponse to treatmentCompensatory response to changesElevated blood glucose levelsNational Institute of DiabetesSecondary analysisMismatch Repair Proficient Colorectal Adenocarcinoma in Two Patients With Lynch Syndrome
Khandakar B, Lacy J, Gibson J. Mismatch Repair Proficient Colorectal Adenocarcinoma in Two Patients With Lynch Syndrome. Clinical Genetics 2024, 107: 469-474. PMID: 39660603, DOI: 10.1111/cge.14670.Peer-Reviewed Original ResearchLynch syndromeColorectal carcinomaResponse to immune checkpoint inhibitorsImpact of molecular classificationImmune checkpoint inhibitorsColorectal carcinoma developmentMismatch repairMicrosatellite instabilityResponse to treatmentPMS2 variantsCheckpoint inhibitorsPembrolizumab treatmentPathological responsePatient AGermline variantsColorectal adenocarcinomaMismatch repair proteinsMolecular classificationLS patientsDNAR-16. TARGETING APOBEC CYTIDINE DEAMINASES TO ENHANCE RADIOSENSITIVITY IN GLIOMA
Marin B, Gujar A, Kocakavuk E, Johnson K, Amin S, Verhaak R. DNAR-16. TARGETING APOBEC CYTIDINE DEAMINASES TO ENHANCE RADIOSENSITIVITY IN GLIOMA. Neuro-Oncology 2024, 26: viii120-viii121. PMCID: PMC11553289, DOI: 10.1093/neuonc/noae165.0467.Peer-Reviewed Original ResearchApolipoprotein B mRNA-editing enzyme catalytic polypeptide-likeRadiation therapyNon-homologous end joiningRecurrent gliomaDNA-dependent protein kinaseMutational signaturesRT-induced DNA damageMonitoring response to treatmentRadiosensitivity in vitroEnhanced radiosensitivity in vitroA3GPromote tumor evolutionResponse to treatmentAutophosphorylation of DNA-dependent protein kinaseAPOBEC mutational signaturesAdult brain tumorsPrimary adult brain tumorGlioma Longitudinal Analysis ConsortiumFamily of cytidine deaminasesRadiosensitizing gliomasAPOBEC3G (A3GNon-homologous end-joining pathwayPost-RTGlioma cell linesWhole-genome sequencingThe Great Controversy of Obstructive Sleep Apnea Treatment for Cardiovascular Risk Benefit: Advancing the Science through Expert Consensus: An Official American Thoracic Society Workshop Report
Cohen O, Kundel V, Barbé F, Peker Y, McEvoy D, Sánchez-de-la-Torre M, Gottlieb D, Bradley T, Suárez-Fariñas M, Zinchuk A, Azarbarzin A, Malhotra A, Schotland H, Gozal D, Jelic S, Ramos A, Martin J, Pamidi S, Johnson D, Mehra R, Somers V, Hoyos C, Jackson C, Alcantara C, Billings M, Bhatt D, Patel S, Redline S, Yaggi H, Shah N. The Great Controversy of Obstructive Sleep Apnea Treatment for Cardiovascular Risk Benefit: Advancing the Science through Expert Consensus: An Official American Thoracic Society Workshop Report. Annals Of The American Thoracic Society 2024, 22: 1-22. PMID: 39513996, PMCID: PMC11708754, DOI: 10.1513/annalsats.202409-981st.Peer-Reviewed Original ResearchObstructive sleep apneaPositive airway pressureRandomized controlled trialsCardiovascular diseaseImpact of obstructive sleep apneaPrevalence of obstructive sleep apneaOSA subtypesSubgroup of OSA patientsObstructive sleep apnea syndromeObstructive sleep apnea treatmentIncidence of comorbid conditionsSleep apnea treatmentCardiovascular risk benefitMulti-modality therapeutic approachSleep clinic patientsPersonalized therapeutic strategiesTreat symptomatic patientsResponse to treatmentSecondary CVD eventsCost-effective diagnosisComposite CVD outcomeOSA patientsPAP adherenceSleep apneaAssessment of symptomsImpact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate Database
Rolles B, Bewersdorf J, Kewan T, Blaha O, Stempel J, Lanino L, Al Ali N, DeZern A, Sekeres M, Uy G, Carraway H, Desai P, Griffiths E, Stein E, Brunner A, McMahon C, Shallis R, Zeidner J, Savona M, Frumm S, Barua S, Chandhok N, Logothetis C, Bidikian A, Getz T, Roboz G, Wang E, Harris A, Amaya M, Hawkins H, Ball S, Grenet J, Xie Z, Madanat Y, Abaza Y, Badar T, Haferlach T, Maciejewski J, Sallman D, Enjeti A, Al-Rabi K, Halahleh K, Hiwase D, Diez-Campelo M, Valcarcel D, Haferlach C, Pleyer L, Kotsianidis I, Pappa V, Santini V, Consagra A, Al-Kali A, Ogawa S, Nannya Y, Della Porta M, Komrokji R, Zeidan A, Stahl M. Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate Database. Blood 2024, 144: 664-664. DOI: 10.1182/blood-2024-208034.Peer-Reviewed Original ResearchComposite complete responseAllo-HCTOverall survivalComplete responseIPSS-MHMA therapyMedian OSResponse criteriaAllogeneic stem cell transplantationPartial hematologic recoveryClinical response criteriaStem cell transplantationHypomethylating agent-based therapyAgent-based therapyClinical practiceCox regression analysisResponse to treatmentAvailability of donorsDecitabine monotherapyImpact OSOS benefitHematologic recoveryAzacitidine monotherapyCell transplantationCombination therapyChitinase 3-like-1 (CHI3L1) in the pathogenesis of epidermal growth factor receptor mutant non-small cell lung cancer
Kamle S, Ma B, Schor G, Bailey M, Pham B, Cho I, Khan H, Azzoli C, Hofstetter M, Sadanaga T, Herbst R, Politi K, Lee C, Elias J. Chitinase 3-like-1 (CHI3L1) in the pathogenesis of epidermal growth factor receptor mutant non-small cell lung cancer. Translational Oncology 2024, 49: 102108. PMID: 39178575, PMCID: PMC11388375, DOI: 10.1016/j.tranon.2024.102108.Peer-Reviewed Original ResearchNon-small cell lung cancerEpidermal growth factor receptorTyrosine kinase inhibitorsEpidermal growth factor receptor mutant non-small cell lung cancerMutant non-small cell lung cancerEpidermal growth factor receptor axisCell lung cancerLung cancerTherapeutic resistanceDownstream targets of EGFRResistance to TKI therapyEpithelial cellsStimulated epidermal growth factor receptorWild type epidermal growth factor receptorTargeting of epidermal growth factor receptorActivating EGFR mutationsChitinase 3-like 1Progression free survivalInduce tumor cell deathEpidermal growth factor receptor activationEffects of EGFR activationInhibited pulmonary metastasisTumor cell deathResponse to treatmentGrowth factor receptorMicroglia: The Drunken Gardeners of Early Adversity
Ahmed S, Polis B, Kaffman A. Microglia: The Drunken Gardeners of Early Adversity. Biomolecules 2024, 14: 964. PMID: 39199352, PMCID: PMC11353196, DOI: 10.3390/biom14080964.Peer-Reviewed Original ResearchEarly life adversityAbnormal immune responseImpact of early life adversityHistory of early life adversityRodent studiesImmune responseNegative childhood experiencesConditions in adulthoodLevels of inflammatory cytokinesLong-term alterationsRefractory responses to treatmentAbnormal brain developmentMicroglial functionResponse to treatmentTraumatic brain injuryResident immune cellsStress reactivityEarly adversityLife adversitySubstance useChildhood experiencesMicroglial inflammatory responseImmune cellsIn adulthoodPeriod of developmentThyroid dysfunction caused by immune checkpoint inhibitors improves cancer outcomes.
García-Goñi M, Vázquez Gutiérrez B, Sanmamed M, Martín-Algarra S, Luis Pérez-Gracia J, Olmedo M, Chumbiauca E, Martín-Calvo N, Galofré J. Thyroid dysfunction caused by immune checkpoint inhibitors improves cancer outcomes. Endocrine Related Cancer 2024, 31 PMID: 39013402, DOI: 10.1530/erc-24-0064.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsImmune-related adverse eventsRisk of progressionOverall survivalPrimary tumorThyroid dysfunctionPatients treated with immune checkpoint inhibitorsCancer patients treated with immune checkpoint inhibitorsAssociated with higher ORRImmune checkpoint inhibitor regimenTreated with atezolizumabLonger overall survivalCox proportional hazards modelsResponse to treatmentProbability of recurrenceMultivariable-adjusted regressionRisk of mortalityProportional hazards modelIndependent of ageCheckpoint inhibitorsRECIST v1.1Higher ORRCombination therapyUrothelial cancerClinical presentationImpact of acute kidney injury response on survival and liver transplant rates in hospitalized patients with cirrhosis awaiting liver transplantation: Results from the HRS-HARMONY consortium
Li X, Ouyang T, Belcher J, Patidar K, Cullaro G, Asrani S, Wadei H, Simonetto D, Regner K, Dageforde L, Przybyszewski E, Wilechansky R, Sharma P, Ufere N, Duarte-Rojo A, Wahid N, Orman E, St. Hillien S, Robinson J, Chung R, Allegretti A, collaborative I. Impact of acute kidney injury response on survival and liver transplant rates in hospitalized patients with cirrhosis awaiting liver transplantation: Results from the HRS-HARMONY consortium. Liver Transplantation 2024, 30: 1106-1115. PMID: 39073567, DOI: 10.1097/lvt.0000000000000445.Peer-Reviewed Original ResearchAKI responseAcute kidney injuryTransplant-free survivalLiver transplantationLT ratesCirrhosis patientsNon-respondersTime of liver transplantationCourse of hospitalized patientsNo responseRetrospective multicenter studyMELD-Na scoreResponse to therapyResponse to treatmentLiver transplant ratesRate of LTOverall survivalMulticenter studyKidney injuryCirrhosis etiologyCirrhosisHospitalized patientsTransplantationPatientsInjury responsePredictive modeling of gene mutations for the survival outcomes of epithelial ovarian cancer patients
C. M, Lavi E, Altwerger G, Lin Z, Ratner E. Predictive modeling of gene mutations for the survival outcomes of epithelial ovarian cancer patients. PLOS ONE 2024, 19: e0305273. PMID: 38976671, PMCID: PMC11230535, DOI: 10.1371/journal.pone.0305273.Peer-Reviewed Original ResearchConceptsEpithelial ovarian cancerEpithelial ovarian cancer patientsEpithelial ovarian cancer casesGene mutation signaturesPlatinum-based chemotherapyThe Cancer Genome AtlasResponse to treatmentOverall survivalGene mutationsMutational signaturesHomologous recombinationSurvival outcomesIncreased sensitivity to platinum-based chemotherapySensitivity to platinum-based chemotherapyAssociated with increased chemoresistanceResistance to platinum-based chemotherapySurvival timeSurvival rateFavorable response to treatmentPlatinum-induced DNA damageKaplan-Meier survival analysisPrediction of survival outcomesOvarian cancer patientsOverall survival ratePrediction of treatment outcome68-OR: Influence of the Type 1 Diabetes Genetic Risk Score on Response to Immunotherapies for Type 1 Diabetes Prevention
REDONDO M, BUNDY B, PARIKH H, YOU L, TRIOLO T, FERRAT L, TEMPLEMAN E, TOSUR M, STECK A, GOTTLIEB P, ONENGUT-GUMUSCU S, RICH S, ORAM R, HEROLD K, KRISCHER J. 68-OR: Influence of the Type 1 Diabetes Genetic Risk Score on Response to Immunotherapies for Type 1 Diabetes Prevention. Diabetes 2024, 73 DOI: 10.2337/db24-68-or.Peer-Reviewed Original ResearchT1D riskAssociated with higher risk of progressionMarkers of response to treatmentNon-HLA single nucleotide polymorphismsEvaluate risk-benefit ratiosHigh risk of progressionGenetic risk scoreSingle nucleotide polymorphismsCox modelType 1 diabetes genetic risk scoreResponse to immunotherapyRisk of progressionIncreased T1D riskAssociated with higher riskResponse to treatmentRisk-benefit ratioInteraction termsT1D preventionType 1 diabetes preventionPrevent T1DTreatment armsHazard ratioScore 2Treated armClinical trialsTP53 Mutations in Acute Leukemias and Myelodysplastic Syndromes: Insights and Treatment Updates.
Santini V, Stahl M, Sallman D. TP53 Mutations in Acute Leukemias and Myelodysplastic Syndromes: Insights and Treatment Updates. American Society Of Clinical Oncology Educational Book 2024, 44: e432650. PMID: 38768424, DOI: 10.1200/edbk_432650.Peer-Reviewed Original ResearchConceptsMissense mutationsResistant to current chemotherapyLoss-of-function effectPhase II trialPhase III trialsAnti-CD47 antibodyAnti-CD123 antibodyResponse to treatmentPressure of chemotherapyApoptosis systemP53 functionChromosome lossTP53 mutationsTruncating mutationsInhibitor therapyMyelodysplastic syndromeOverall survivalII trialIII trialsSelection pressureAnti-CD123Acute leukemiaAML casesDismal diseaseImproved survivalNatural resistance to meglumine antimoniate is associated with treatment failure in cutaneous leishmaniasis caused by Leishmania (Viannia) panamensis
Fernández O, Rosales-Chilama M, Sánchez-Hidalgo A, Gómez P, Rebellón-Sánchez D, Regli I, Díaz-Varela M, Tacchini-Cottier F, Saravia N. Natural resistance to meglumine antimoniate is associated with treatment failure in cutaneous leishmaniasis caused by Leishmania (Viannia) panamensis. PLOS Neglected Tropical Diseases 2024, 18: e0012156. PMID: 38709850, PMCID: PMC11098511, DOI: 10.1371/journal.pntd.0012156.Peer-Reviewed Original ResearchConceptsAssociated with treatment failureTreatment failureHost risk factorsBALB/c miceRisk factorsDrug susceptibilityClinical strainsOutcome of cutaneous leishmaniasisOdds of treatment failureMeglumine antimoniateParasitological response to treatmentLeishmania (Viannia) panamensisSubgroup of patientsAntimicrobial drug susceptibilityResponse to treatmentU937 macrophagesEvaluate drug susceptibilityCutaneous leishmaniasis patientsCutaneous leishmaniasisFailed treatmentPlasma CmaxTherapeutic responseClinical outcomesPatient's lesionsTreatment outcomesNeuromarkers in addiction: definitions, development strategies, and recent advances
Harp N, Wager T, Kober H. Neuromarkers in addiction: definitions, development strategies, and recent advances. Journal Of Neural Transmission 2024, 131: 509-523. PMID: 38630190, DOI: 10.1007/s00702-024-02766-2.Peer-Reviewed Original ResearchConceptsSubstance use disordersFeatures of substance use disordersResponse to treatmentNeurobiological basisAddiction neuroscienceIndividual treatment outcomesPsychiatric conditionsDetecting response to treatmentPsychological phenomenaNeuromarkersIndex riskSeverity of pathologyTreatment outcomesAbnormal processingAddictionPutative markerClinical practiceStable indicatorSevere pathologyAssess riskNeurosciencePathologyReview recent advancesDisordersTreatmentCase-Control Study of Individuals With Small Fiber Neuropathy After COVID-19
McAlpine L, Zubair A, Joseph P, Spudich S. Case-Control Study of Individuals With Small Fiber Neuropathy After COVID-19. Neurology Neuroimmunology & Neuroinflammation 2024, 11: e200244. PMID: 38630952, PMCID: PMC11087026, DOI: 10.1212/nxi.0000000000200244.Peer-Reviewed Original ResearchConceptsInvasive cardiopulmonary exercise testingSmall fiber neuropathyCase-control studyFiber neuropathySkin biopsiesClinical response to treatmentNeurovascular dysregulationTreated with IVIGRetrospective chart reviewCase-control study of individualsRetrospective cohort studyResponse to treatmentCardiopulmonary exercise testingClass III evidenceMyalgic encephalomyelitis/chronic fatigue syndromeIVIG groupClinical responseNeuropathic symptomsChart reviewIVIGStudy of individualsCohort studyIII evidenceClinical trialsCOVID-19 illnessThree- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide
Parikh M, Tangen C, Hussain M, Gupta S, Callis S, Jo Y, Harzstark A, Paller C, George S, Zibelman M, Cheng H, Maughan B, Zhang J, Pachynski R, Bryce A, Lin D, Quinn D, Lerner S, Thompson I, Dorff T, Lara P, Agarwal N. Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide. European Urology Oncology 2024, 7: 1097-1104. PMID: 38523017, DOI: 10.1016/j.euo.2024.03.001.Peer-Reviewed Original ResearchMetastatic hormone-sensitive prostate cancerHormone-sensitive prostate cancerProstate-specific antigenAndrogen deprivation therapyProstate-specific antigen levelOverall survivalProstate cancerDeprivation therapyComplete responseAntigen levelsNo responseTreatment of metastatic hormone-sensitive prostate cancerLow prostate-specific antigen levelsResponse to androgen deprivation therapyAssociated with improved OSPSA responsePhase 3 randomized trialPhase 3 clinical trialsEarly identification of patientsAssociated with OSHigher risk of deathIdentification of patientsResponse to treatmentRisk of deathOS associationSecond‐line immunotherapy in new onset refractory status epilepticus
Hanin A, Muscal E, Hirsch L. Second‐line immunotherapy in new onset refractory status epilepticus. Epilepsia 2024, 65: 1203-1223. PMID: 38430119, DOI: 10.1111/epi.17933.Peer-Reviewed Original ResearchFebrile infection-related epilepsy syndromeSecond-line immunotherapyOnset refractory status epilepticusRefractory status epilepticusIntrathecal dexamethasoneStatus epilepticusCytokine levelsFunctional outcomesCerebrospinal fluid cytokine levelsInitiation of anakinraReduction of seizure frequencyLong-term functional outcomeResponse to treatmentSE onsetElevated serumFebrile infectionsImmune dysregulationLong-term disabilityTreatment initiationCase reportCytokine measurementsProspective studyAnakinraImmunotherapyTocilizumab
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply